Seven research firms currently cover Integra LifeSciences, assigning an average rating of “Reduce.” Three analysts have issued sell ratings, two maintain hold ratings and two have buy ratings. The average 12-month price objective across these reports stands at $15.00. Notable updates include Weiss Ratings reaffirming a sell (e+) rating on December 29, Wall Street Zen upgrading from hold to buy on November 8, and JPMorgan Chase & Co. raising its target from $12.00 to $13.00 while keeping an underweight stance on October 31. Citigroup trimmed its target from $12.00 to $11.00 and upheld a sell rating on the same day, and Truist Financial lowered its target from $15.00 to $13.00 with a hold designation on November 3.

In its third quarter, Integra reported adjusted earnings per share of $0.54, surpassing consensus estimates by $0.11. Revenue came in at $402.1 million, a 5.6% increase year-over-year but falling short of the $414.3 million expected by analysts. The company posted a negative net margin of 30.15% yet achieved a 14.06% return on equity. Management set guidance for the fourth quarter at $0.79 to $0.84 EPS and full-year guidance of $2.19 to $2.24 EPS. Analysts currently project full-year EPS of $2.45.

Director Jeffrey A. Graves purchased 9,000 shares on November 5 at an average cost of $11.35 per share, increasing his holdings by 28.05% to 41,086 shares. Insider ownership now represents 3.54% of the company’s shares. On the institutional front, Mirae Asset Global ETFs boosted its stake by 5.1% in Q1, acquiring an additional 1,975 shares. Dynamic Technology Lab initiated a position valued at $277,000, while Goldman Sachs increased its holdings by 2.2% to 1.66 million shares. UBS Asset Management added 45,693 shares (a 23.0% increase), and STRS Ohio entered with a new $400,000 position. Overall, institutional investors hold 84.78% of the company’s shares.